Rapport Therapeutics
RAPP
30.86
-0.29
-0.93%
Rapport Therapeutics
US · RAPP
#2970 by market cap
Listed 2024
30.86
-0.29
-0.93%
Live - 5344 symbols - heartbeat 386s ago
· 2026-10-08 07:00
Pre-market
31.71
+2.75%
After-hours
30.86
0.00%
Overnight
30.86
0.00%
- Market cap
- 1.48B
- P/E (TTM)i
- -10.18
- P/Bi
- 3.50
- EPSi
- -2.86
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on RAPP?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 4 years
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | -- | 8.18M | 22.12M | 30.31M |
| Research & development | -- | 28.00M | 60.94M | 94.79M |
| Operating profit | -- | -36.18M | -83.06M | -125.10M |
| Pretax profit | -- | -34.78M | -78.31M | -111.48M |
| Tax | -- | 10.00K | -- | -- |
| Net profit | -- | -34.79M | -78.31M | -111.48M |
| Basic EPS | -- | -23 | -4 | -3 |
| Diluted EPS | -- | -23.10 | -3.78 | -2.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | -- | -- | 20.00M | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.54M | 6.82M | 7.71M | 8.25M | 11.50M | 9.39M |
| Research & development | 19.57M | 22.68M | 22.28M | 30.26M | 32.72M | 51.41M |
| Operating profit | -27.11M | -29.50M | -29.99M | -38.51M | -24.22M | -60.81M |
| Pretax profit | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Basic EPS | -1 | -1 | -1 | -1 | 0 | -1 |
| Diluted EPS | -0.68 | -0.75 | -0.71 | -0.72 | -0.42 | -1.19 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 31.27M | 150.87M | 309.80M | 498.56M |
| Cash & ST investments | 31.16M | 147.48M | 305.28M | 490.54M |
| Inventory | -- | -- | -- | -- |
| Total assets | 31.60M | 155.42M | 314.93M | 512.43M |
| Total current liabilities | 1.66M | 8.80M | 8.77M | 19.05M |
| Short-term debt | -- | 670.00K | 737.00K | 2.76M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 41,665,000.00 | 181,057,000.00 | 9,506,000.00 | 27,778,000.00 |
| Total equity | -10.06M | -25.63M | 305.43M | 484.65M |
| Retained earnings | -10.65M | -45.44M | -123.75M | -235.23M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 290.97M | 270.24M | 520.66M | 498.56M | 484.70M | 446.86M |
| Cash & ST investments | 285.38M | 260.45M | 513.03M | 490.54M | 476.78M | 436.08M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 302.05M | 285.50M | 535.32M | 512.43M | 497.60M | 458.98M |
| Total current liabilities | 9.38M | 11.88M | 14.32M | 19.05M | 17.90M | 28.42M |
| Short-term debt | 1.01M | 1.76M | 2.48M | 2.76M | 2.62M | 2.47M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 16,217,000.00 | 21,983,000.00 | 23,706,000.00 | 27,778,000.00 | 26,085,000.00 | 36,056,000.00 |
| Total equity | 285.84M | 263.51M | 511.62M | 484.65M | 471.51M | 422.93M |
| Retained earnings | -147.81M | -174.54M | -201.47M | -235.23M | -255.09M | -311.70M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -- | -27.18M | -64.83M | -87.47M |
| Depreciation & amortization | -- | 112.00K | 839.00K | 1.02M |
| Free cash flow | -- | -28.82M | -67.23M | -88.09M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 50.00K | 157.71M | 269.44M |
| Ending cash balance | -- | 70.25M | 56.91M | 52.75M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -20.24M | -25.07M | -17.47M | -24.70M | -13.06M | -41.46M |
| Depreciation & amortization | 244.00K | 252.00K | 256.00K | 265.00K | 227.00K | 212.00K |
| Free cash flow | -20.53M | -25.09M | -17.60M | -24.87M | -13.15M | -41.53M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.00K | 0 | 269.83M | -395.00K | -5.00K | 0 |
| Ending cash balance | 57.71M | 55.17M | 251.46M | 52.75M | 78.16M | 63.72M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -55.98 | -28.22 |
| ROA %i | -- | -37.20 | -33.30 | -26.95 |
| ROIC %i | -- | -- | -63.83 | -31.16 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 18.80 | 17.14 | 35.34 | 26.17 |
| Quick ratioi | 18.74 | 16.75 | 34.82 | 25.75 |
| Debt / assetsi | 0.00 | 1.38 | 0.47 | 2.24 |
| LT debt / equityi | -- | -- | 0.24 | 1.80 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -64.74 | -29.42 | -23.41 | -28.22 | -28.33 | -39.96 |
| ROA %i | -31.36 | -27.96 | -22.55 | -26.95 | -26.83 | -36.85 |
| ROIC %i | -72.70 | -33.14 | -25.96 | -31.16 | -31.50 | -43.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -611.03 | -767.58 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 31.01 | 22.75 | 36.37 | 26.17 | 27.08 | 15.72 |
| Quick ratioi | 30.41 | 21.92 | 35.84 | 25.75 | 26.64 | 15.35 |
| Debt / assetsi | 2.60 | 4.16 | 2.22 | 2.24 | 2.17 | 2.20 |
| LT debt / equityi | 2.39 | 3.83 | 1.84 | 1.80 | 1.74 | 1.80 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing medicines for patients with neurological or psychiatric disorders100.00%
Quote time 2026-10-08 07:00:02 · For reference only, not investment advice and not tailored to your situation.